For the primary endpoint, Eczema Area and Severity Index (EASI) improved by 53-61% in a dose-dependent manner across the ...

New data show that dual-target CAR T therapy induces durable remissions in children with high-risk B-cell leukaemia, offering ...

Preexisting autoimmune diseases are tied to shorter hospital stays and less toxicity risk in patients receiving chimeric ...

New investors Tencent and BGF joined by all existing major shareholdersFunds will advance pipeline of novel TCR-CD3 bispecifics in cancer and autoimmune disease 13 November 2025; Cambridge, England – ...

CU Anschutz researchers uncovered a link between a type of mucosal immune cell and gut inflammation, finding that the cells ...

Jay Lalezari, CEO of CytoDyn, explains how the CCR5 receptor has emerged as a pivotal target in metastatic cancers due to its ...

A physician-scientist who last year joined the University of Colorado Cancer Center team will soon steer the first human ...

In this interview, Dr. Kelemen discusses the advantages of lipid-based delivery systems and their potential to expand the ...

The treatment landscape for systemic lupus erythematosus (SLE) has shifted greatly in recent years, driven by the emergence ...

In Alzheimer’s disease, microglia act as a double-edged sword. They can either protect the brain or worsen the damage, ...

SynKIR™-110 exhibited reduced cell exhaustion, lower off-target toxicity, and robust tumor regression in vitro and in vivo ...

In an interview with Targeted Oncology, Frederick L. Locke, MD, discussed how the elimination of the REMS program for CAR T-cell therapy came about and what effects he hopes this will have on patient ...